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Heart developmentof specialized cardiomyocytes located within the sinoatrial node (SAN), and is
responsible for originating and regulating the heart beat. Recent advances towards understanding the SAN
development have been made on the genetic control and gene interaction within this structure. Here we
report that the Shox2 homeodomain transcription factor is restrictedly expressed in the sinus venosus region
including the SAN and the sinus valves during embryonic heart development. Shox2 null mutation results in
embryonic lethality due to cardiovascular defects, including an abnormal low heart beat rate (bradycardia)
and severely hypoplastic SAN and sinus valves attributed to a signiﬁcantly decreased level of cell
proliferation. Genetically, the lack of Tbx3 and Hcn4 expression, along with ectopic activation of Nppa, Cx40,
and Nkx2-5 in the Shox2−/− SAN region, indicates a failure in SAN differentiation. Furthermore, Shox2
overexpression in Xenopus embryos results in extensive repression of Nkx2-5 in the developing heart,
leading to a reduced cardiac ﬁeld and aberrant heart formation. Reporter gene expression assays provide
additional evidence for the repression of Nkx2-5 promoter activity by Shox2. Taken together our results
demonstrate that Shox2 plays an essential role in the SAN and pacemaker development by controlling a
genetic cascade through the repression of Nkx2-5.
© 2008 Elsevier Inc. All rights reserved.Introduction
During embryonic heart development, the fused linear primitive
heart tube contracts spontaneously, randomly and irregularly begin-
ning at embryonic day 8.0 (E8.0). By E9.0 the heart beat becomes
organized and regular with a caudal to cranial directionality (van
Mierop, 1967; Nishii and Shibata, 2006). The regularity of the heart
beat coincides with the “maturation” of the cardiac pacemaker located
in the caudal region of the linear heart tube, the sinus venosus (van
Mierop, 1967) and eventually becomes restricted to the right dorsal
wall of the right atrium, structurally known as the sinoatrial node
(SAN) (van Mierop, 1967; van Mierop and Gessner, 1970). Deﬁciencies
in such pacemaking function lead to cardiac defects specially
arrhythmias and in severe cases to cardiac arrest and sudden death
(Durham and Worthley, 2002).
Genetically, the SAN is characterized by the expression or lack
thereof of several molecular markers. The hyperpolarization-gated
cyclic nucleotide cation-activated channel, Hcn4, a speciﬁc molecular
marker for the pacemaker (Santoro and Tibbs, 1999) is expressed asl rights reserved.early as E7.5 in the cardiac crescent, becoming restricted to the sinus
horns of the sinus venosus and eventually to the SAN region by E12.5
(García-Frigola et al., 2003). Hcn4 mutant mice die at mid-gestation
stage due to the lack of formation of a “mature” pacemaker, while its
overexpression mimics pacemaker properties in cell cultures (Santoro
and Tibbs, 1999; Santoro et al., 2000; Moosmang et al., 2001; Stieber et
al., 2003; Liu et al., 2007). The T-box transcription factor Tbx3, has been
reported to be expressed in the cardiac conduction system including the
SAN (Hoogaars et al., 2004). Mutation of the Tbx3 gene causes limb and
mammary deformities and embryonic lethality due to cardiovascular
defects (Davenport et al., 2003), however, does not impair the early
formation of the SAN in mice (Hoogaars et al., 2007). Moreover, Tbx3
was shown to repress the expression ofNppa (ANF) and Cx40 by directly
binding to the promoter of each gene in cultured cells (Hoogaars et al.,
2004). Indeed, the expression ofNppa and Cx40 is mutually exclusive to
that of Tbx3 in the heart (van Kempen et al., 1996; Gaussin, 2004;
Soufan et al., 2004; Stennard and Harvey, 2005). The early cardiac
differentiation marker Nkx2-5 is expressed as early as the formation of
the cardiac crescent (Komuro and Izumo, 1993; Moses et al., 2001).
However, it is not expressed in the SAN or in the venous valves
(Kasahara et al., 1998). Mice deﬁcient in Nkx2-5 are embryonically
lethal due to disruption in the differentiation of cardiac tissue (Lyons et
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myocytes characteristics in rat myocardial cultures (Wang et al., 2007).
Additionally, haploinsufﬁciency and point mutations in the human
Nkx2-5 gene are related to arrhythmias and atrioventricular conduction
deﬁciencies (Schott et al., 1998; Benson et al., 1999; Watanabe et al.,
2002). Nkx2-5, Tbx3 and Hcn4 have been integrated in a genetic
network involved in the development and patterning of the SAN
(Hoogaars et al., 2007; Mommersteeg et al., 2007).
Shox2, formerly known as Og12 in mice (Rovescalli et al., 1996), Prx3
in rats (van Schaick et al., 1997) and SHOT in humans (Blaschke et al.,
1998), is closely related to the short stature homeobox gene SHOX, both
being present only in vertebrates; however, a SHOX ortholog is absent in
the mouse. Mutations in either SHOX or Shox2 cause skeletal and other
abnormalities, particularly in the long bones (Ellison et al., 1997; Rao et
al., 2001; Belin et al., 1998; Shears et al., 1998; Zinn et al., 2002; Yu et al.,
2005, 2007; Cobb et al., 2006; Gu et al., 2008). Shox2 has been shown to
be expressed in the SAN; its null mutation causes embryonic lethality
and ectopic expression ofNkx2-5 and Cx40 in the SAN region, suggesting
a possible role in the differentiation of this structure (Blaschke et al.,
2007). However the detailed relationship between Shox2 and the
development of the SAN is still not complete and the Shox2 molecular
niche in such a process is still not clear.
In this study we show that Shox2 expression is restricted to the
sinus venosus region, and eventually to the SAN, including the
pacemaker and sinus valves in the developing mouse heart. Shox2
null mutation leads to cardiac edema, vascular defects, hypoplasia of
the SAN and sinus valves as well as severe bradycardia. Gene
expression analyses of molecular markers reveal failure in the
differentiation of pacemaker cells and absence of a deﬁned SAN in
the Shox2 mutant hearts. Shox2 overexpression represses the expres-
sion ofNkx2-5 in cell cultures, and in Xenopus embryos leads to cardiac




Generation of Shox2 mutant mice has been described previously
(Yu et al., 2005). Shox2 heterozygotes weremaintained on both C57BL/
6 and CD-1 genetic backgrounds. Histological analyses and compar-
isonswere performed usingwild type (WT), and Shox2−/−mice on both
genetic backgrounds. Embryos were collected at different embryonic
stages for examination of death rate. Embryonic age was determined
by counting the appearance of vaginal plug as embryonic day 0.5 (E
0.5). Genotyping was performed by PCR using genomic DNA extracted
from tail biopsies or from the amniotic membrane as described
previously (Yu et al., 2005). Xenopus laevis eggs were obtained from
hormone-stimulated females, fertilized in vitro, and cultured following
a standard procedure (Sive et al., 2000). Embryos were reared in 0.1×
Marc's Modiﬁed Ringer's solution (MMR) at 25 °C until desired stages.
Embryo staging was determined according to Nieuwkoop and Faber
(1967). Microinjection was performed in 3% Ficoll solution; mRNA
encoding GR-Shox2 (50 pg) was injected into themarginal zone of two
dorsal blastomeres at the 4-cell stage. At the early neurula stage,
control and injected embryos were divided into two groups, with one
group cultured in 0.2× MMR, while the other group cultured in 0.2×
MMR containing 10 μMdexamethasone (Sigma) (Kolm and Sive,1995).
Embryos were harvested at the tadpole stage, processed and analyzed
for gene expression by in situ hybridization.
Histology, in situ hybridization, detection of cell proliferation
and apoptosis
Wild type and Shox2−/− embryos on C57BL/6 or CD-1 backgrounds
were collected in DEPC-treated PBS, ﬁxed in 4% paraformaldehyde(PFA) in DEPC-treated PBS overnight at 4 °C, dehydrated in a series of
alcohol, cleared in xylene and embedded in parafﬁn wax. Embryos
were sectioned at 7 μm–10 μm and subjected to either Hematoxilin/
Eosin staining or in situ hybridization after deparafﬁnation and
rehydration as described previously (Alappat et al., 2005). Xenopus
embryos were similarly treated; however, dehydration in methanol
series was used for whole mount in situ hybridization. Samples for in
situ hybridization were hybridized with antisense RNA probes for
mouse Tbx3 (provided by Dr. KenMuneoka, Tulane University), mouse
Nkx2-5 and Nppa (provided by Dr. Eric Olson's laboratory, South-
western Medical Center, University of Texas), Xenopus Nkx2-5 and cTnI
(provided by Dr. Frank Conlon's laboratory, University of North
Carolina-Chapel Hill). Other probes used were cloned by RT-PCR in
our laboratory and sequence conﬁrmed. Cell proliferation rate was
detected by in vivo BrdU labeling using a BrdU Labeling and Staining
Kit following the manufacturer's instruction (Roche Applied Sciences,
IN), and cell apoptosis was detected by using a Cell Death Detection Kit
(Roche Applied Sciences, IN), as previously described (Yu et al., 2005;
Alappat et al., 2005). To obtain consistent results, all the experiments,
including in situ hybridization, BrdU labeling, and TUNEL assays were
repeated at least three times. For BrdU labeling studies, BrdU-positive
cells were counted and presented as percentage of total cells within
the selected areas. Nine sections from three individual samples of
either wild type or mutant were counted and applied to statistical
calculation. The Student's t-test was used to determine signiﬁcant
statistical difference.
Measurement of heart beat rate
For measurement of heart beat rate, embryonic hearts were
isolated and cultured according to a standard method as previously
described (Stieber et al., 2003). Brieﬂy, embryos at E9.5 and E10.5
were dissected in pre-warmed ADS buffer containing glucose. Hearts
were excised and cultured in DMEM containing 10% FBS and 1%
antibiotics at 37 °C and 10% CO2 for 24 h. Heart beats were counted
under inverted microscope for 10 s three times for each heart before
the genotypewas known, thus assuring a blind heart beat count. Heart
beat counts were converted to heart beats per minute and statistical
analysis was performed using the Student's t-test for determination of
statistical difference.
Plasmid constructs
The Shox2a coding sequence was ampliﬁed by PCR using Pfu high
ﬁdelity enzyme (Strategene) and inserted into the pcDNA3 vector
(Invitrogen) containing a myc tag in order to create the myc-Shox2
construct. To make the dexamethasone inducible fusion protein
version of Shox2 (GR-Shox2), the Shox2a coding sequence was cloned
into the pCS2+_GR vector, which contains the glucocorticoid ligand-
binding domain (amino acids 513–777). The 3.3-kb mouse Nkx2-5
upstream sequence driving the expression of the Luciferase gene
(Nkx2-5-Luc) (Liberatore et al., 2002) was provided by Dr. Katherine
Yutzey (Cincinnati Children's Hospital Medical Center) and utilized in
subsequent experiments. Site-directed mutagenesis was carried out on
the Nkx2-5-luc construct by PCR using Pfu high ﬁdelity enzyme
following the manufacturer's instructions (Stratagene) and the





3′. Truncated derivatives of the Nkx2-5-luc construct were obtained
by digesting plasmid DNA with KpnI and BstEII (2.9-kb) or NruI (2.1-
kb) restriction endonucleases, ﬁlled in by Klenow fragment and re-
ligated using T4 ligase. The resulting constructs were veriﬁed by
sequence analysis.
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Rat cardiomyocytes were isolated from neonatal Sprague–Dawley
rat hearts using a cardiomyocyte isolation kit (Worthington Biochem-
ical, NJ) following the manufacturer's instructions. H9c2 embryonic
rat-heart derived cell line was obtained from American Tissue Culture
Collection (ATCC — Manassas, VA). Cell cultures were maintained in
DMEM supplemented with 10%FBS, with or without antibiotics, at
37 °C and 5% CO2. H9c2 cell cultures were not allowed to reach
conﬂuency to avoid differentiation and myoblast formation. Transfec-
tions were performed in triplicate in each experiment using Fugene6
(Roche) or Lipofectamine (Invitrogen) reagents following the manu-
facturer's instructions. Cell cultures were lysated 48 h post-transfec-
tion with Luciferase Reporter lysis buffer (Promega). CMV-LacZ
reporter vector was used as an internal control and LacZ activity
was used for normalizing transfection results. Experiments were
repeated twice.
Results
Shox2 expression in the developing heart
Shox2 expression has been reported to be restricted to the SAN,
sinus valves and branches of the central conduction system in mouse
and embryonic heart and (Blaschke et al., 1998, 2007; Semina et al.,
1998; Clement-Jones et al., 2000). We analyzed a detailed Shox2
expression pattern in the early developing mouse heart by in situ
hybridization. Shox2 expressionwas not detectable in the heart at E8.0
(data not shown), but was found in a restricted pattern at the junction
formed by the common cardinal vein and the common atrial chamber,
the sinus venosus, at E8.5 (Fig. 1A). Subsequently, cardiac heart
looping and remodeling brings the sinus venosus to the right side of
the heart and Shox2 expression extends to the sinus valves originating
from the sinus node at E10.5 (Fig.1B). At E11.5 the sinus valves develop
to a deﬁnite structure, Shox2 expression becomes speciﬁcally
restricted to the SAN and to the venous layers of the sinus valves
(Fig. 1C). At E12.5 and later in development the expression patternFig. 1. Shox2 expression in the murine developing heart. (A) Shox2 expression is initially dete
Shox2 expression gradually becomes restricted to the right side of the heart to the dorsal wa
E12.5 (D), restricted Shox2 expression in the SAN and sinus valves (arrowheads) is clearly o
Whole mount in situ hybridization showing the expression of Shox2a isoform in the sinus vremains consistently in the SAN region and the sinus valves (Figs. 1D,
E). Nucleotide sequence analysis suggests that the Shox2 gene
generates two isoforms by alternative splicing, Shox2a and a shorter
version Shox2b (Rovescalli et al., 1996; Blaschke et al., 1998). Both
isoforms contain the sequence coding for the homeodomain, an SH3
binding domain, and P-loop binding domain. However, Shox2b lacks
363 nucleotides which correspond to the N-terminus unique to
Shox2a. By using this sequence as a Shox2a speciﬁc probe, we were
able to detect Shox2a expression in the sinus venosus region (Fig. 1F).
It is noteworthy to mention that our analysis showed a very restricted
Shox2 expression pattern, but could not conﬁrm the presence of Shox2
in the primitive bundle branches of the cardiac conduction system, as
reported by Blaschke et al. (2007).
Shox2-deﬁcient mice die at mid-gestation and exhibit morphological
abnormalities
We have previously reported that on C57BL/6 background, 63% of
Shox2 homozygous embryos died between E11.5 and E12.5, while
few embryos survive up to E17.5 (Yu et al., 2005). Interestingly, we
have found that on CD1 background, about 78% of the embryos die
between E11.5 and E12.5 and no surviving embryos were found
beyond E13.5. Embryonic mortality is attributable to cardiovascular
defects evidenced by cardiac and vascular edema (Figs. 2A, B arrows).
Histological analyses demonstrate that at E10.5 the Shox2−/− hearts
from both genetic backgrounds show no obvious structural differ-
ences when compared to wild type embryos (WT). However, the
mutant forming sinus valves show a slight difference (data not
shown). At E11.5, the Shox2−/− hearts from both genetic backgrounds
exhibit severe hypoplasia of the sinus valves, thinner atrial walls and
enlargement of the right atrium in some specimens (Figs. 2C, D; and
data not shown). In the most severe cases, the sinus valves were
almost absent (Fig. 2D). In addition, the SAN region is also hypoplastic,
as evidenced by its markedly reduced size (Figs. 2C, D, arrows). The
cardiac defect observed in Shox2−/− mice on C57BL/6 background is
relatively milder in comparison to the Shox2−/− hearts on CD-1
background (data not shown), which possibly accounts for thected in the sinus venosus region (arrowhead) at E8.5 embryo. At E10.5 (B) and E11.5 (C),
ll of the right atrium, the SAN region (arrow, C) and sinus valves (arrowheads, B, C). At
bserved. (E) Shox2 expression at E16.5 follows the same pattern as previous stages. (F)
enosus region (yellow arrowhead). A, atrium; V, ventricle; D, dorsal side.
Fig. 2. Shox2 deﬁciency causes embryonic lethality and cardiac morphological and functional abnormalities. (A, B) Panoramic comparison between a wild type (A) and a Shox2−/− (B)
embryos at E11.5. The mutant embryo exhibits cardiac edema (arrow) and vascular defects (arrowheads). Brain defects are observed in some specimens. (C, D) Histological
comparison shows hypoplastic SAN and sinus valves in the Shox2−/− mutant heart (red arrowheads in panel D), as compared to the wild type controls (C), evidenced by the length of
the sinus valves (red arrows in panels C and D) and the difference in size of the SAN region (black arrows in panel D). Additionally, a thinner atrial wall and an enlarged atrial chamber
were observed in the Shox2−/− heart (D). (E, F) BrdU labeling shows a signiﬁcantly decreased level of cell proliferation in the Shox2−/− SAN and sinus valves (F), as compared to the wild
type (E). (G) Comparison of the percentage of BrdU-positive cells present in the SAN and sinus valves demonstrate a signiﬁcant difference between wild type and Shox2−/− hearts
(⁎: Pb0.05); the interventricular septum region was chosen as a control region shows no signiﬁcant difference. (H) Measurement of the contraction rate in isolated hearts at E10.5
after 24 h of culture shows a signiﬁcantly slower beating rate in the Shox2−/− samples, as compared to the wild type (wt) and Shox2 heterozygote (het) samples (⁎: Pb0.001).
A, atrium; bpm=beats per minute. Scale bars represent 1 mm (A, B) or 50 μm (C–F).
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Shox2−/− embryos on C57BL/6 background that survived to late
developmental stages, severe cardiac abnormalities were observed,
including defective myocardial wall and signiﬁcantly enlarged right
atrium (data not shown). For all subsequent experiments we chose to
use Shox2−/− embryos on CD-1 background which exhibit more severe
cardiac abnormalities.
Shox2−/− mice show reduced growth in the SAN region
Shox2 expression in the developing heart is restricted to the sinus
venosus, SAN and sinus valves. Histological analyses demonstrate
severe abnormalities in these structures of Shox2 mutants, consistent
with Shox2 expression pattern. To identify the cellular defects that
contribute to the formation of the hypoplastic SAN and sinus valves,
we examined the levels of both cell proliferation and apoptosis in the
heart of wild type and Shox2−/− embryos at E11.5 by BrdU labeling and
TUNEL assays. As a control region, BrdU-positive cells were counted
in the interventricular septum myocardium, which does not express
Shox2 and does not present obvious structural differences when the
control and Shox2−/− mutant hearts were compared. Although the
level of apoptosis was not altered (data not shown), a dramaticallyreduced level of cell proliferation was observed in the mutant SAN
and sinus valves, as compared to their wild type controls (Figs. 2E, F,
arrows). Cell counting for BrdU-positive cells and total number of
cells in the mentioned regions show that the percentage of
proliferating cells is signiﬁcantly different in the mutant hearts
(9.9%±3.6%) when compared to the wild type controls (18.9%±1.0%).
Similar analysis show no signiﬁcant difference in the percentage of
proliferating cells in the interventricular septum myocardium
(wt=31.9%±5.5%; Shox2−/−=3.4%) (Fig. 2G).
Shox2−/− hearts present a slower heart beat rate
Morphological defects observed in the SAN region of the Shox2−/−
hearts strongly suggest that the cardiac pacemaker is dysfunctional.
We examined the heart beat rate, an index of the pacemaker
function (Stieber et al., 2003) in isolated hearts individually
cultured in vitro for 24 h. The heart beat rate of each sample was
counted before the genotype was determined. Analysis on embryo-
nic hearts of E9.5 embryos yielded no signiﬁcant difference in heart
beat rates observed in Shox2 mutants as compared to those of wild
type and Shox2 heterozygotes (data not shown). However, analysis
on embryonic hearts of E10.5 embryos revealed this defect in
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contracted regularly, Shox2−/− hearts (n=8) were contracting slower
than wild type (n=10) and heterozygote hearts (n=36) (Fig. 2H).
The heart beat rate in the mutant (69.75±12.40 beats per minute—
bpm) was less than 50% of that in the wild type (165±31.65 bpm)
and heterozygote hearts (154±35.61 bpm), respectively. This cardiac
abnormality observed in Shox2−/− hearts exhibit similar character-
istics to human bradycardia cases (Watanabe et al., 2002; Milanesi
et al., 2006) and to those found in the mouse Hcn4−/− model
(Stieber et al., 2003).
Shox2 is a key regulator in pacemaker differentiation
Genetically the SAN and pacemaker region in the developing
embryo have been generally determined by a combination of the
expression or lack thereof of severalmolecules to deﬁne its boundaries.
Thus, to investigate the role of Shox2 in the development of the SAN,
we examined the expression of several genes that have been used to
identify the SAN or known to play a role in its formation and function
(Soufan et al., 2004). These include Hcn4, a speciﬁc molecular marker
for the pacemaker; Tbx3, a molecular marker for the cardiac
conduction system including the SAN; the early cardiac differentiation
marker Nkx2-5, expressed in the myocardium, but not in the SAN
(Kasahara et al., 1998), Nppa (also known as atrial natriuretic factor—
ANF), a chamber differentiation marker that is absent in the pace-
maker; and Cx40 whose high expression represents areas of con-
ductivity outside the SAN region. Our results reveal that expression of
Hcn4 in the SAN,while remaining unchanged at E10.5 (Figs. 3A, B), wasFig. 3. Altered gene expression in the Shox2−/− heart. Expression patterns of Hcn4 (A–D), Tbx3
wild type and Shox2−/− hearts are shown. Hcn4 is expressed in the dorsal right wall of the righ
is expressed in the dorsal right wall of the right atrium and in the sinus valves (E, G), how
ectopically expressed in the dorsal right wall of the Shox2–/– right atrium at both stages (J, N,
expression level in the Shox2–/– heart (V, X) and the wild type controls (U, W). In all panels,
atrium. Scale bars represent 50 μm.severely reduced at E11.5 in Shox2−/− hearts (Figs. 3C, D). Tbx3 was
speciﬁcally down-regulated in the SAN region and the sinus valves in
the Shox2−/− hearts (Figs. 3F, H), as compared to the wild type
counterparts at both stages (Figs. 3E, G). Nkx2-5 was not expressed in
the SAN of wild type embryos (Figs. 3I, K), but was ectopically
expressed in the Shox2−/− SAN at E10.5 and E11.5 (Figs. 3J, L), in
concordance to results obtained by Blaschke et al. (2007). Nppa and
Cx40, the direct Tbx3 transcription targets, and whose expression
patterns are mutually exclusive to that of Tbx3 (Rovescalli et al., 1996;
van Kempen et al., 1996), were ectopically activated in themutant SAN
and sinus valves at low levels at E10.5 (Figs. 3N, R) and markedly
expressed at E11.5 (Figs. 3P, T), as compared to the wild type controls
(Figs. 3M, Q, O, S). In contrast, expression of the pan-marker for
differentiated cardiomyocytes cardiac Troponin T (cTnt) (Wang et al.,
1994; Jiao et al., 2003;Wang et al., 2001), was unaltered in the Shox2−/−
hearts, as compared to the wild type samples (Figs. 3U–X). We also
analyzed the expression of two other cardiacmarkers,MLC2a, amarker
for differentiated atrial myocardium (Yutzey et al., 1994; Doevendans
et al., 2000), and MLC2v, a marker for differentiated ventricular
myocardium (O'Brien et al., 1993; Kubalak et al., 1994). These two
genes showed no changes in expression in the mutants (data not
shown). These observations demonstrate that cardiomyocyte differ-
entiation is not affected in the absence of Shox2. The reduced
expression of Hcn4 at E10.5 and the absence of Hcn4 expression at
E11.5 in Shox2mutants, alongwith the fact thatHcn4 is required for the
regulation of a normal heart beat (Stieber et al., 2003) appear to
account for the slow ﬁring of the SANwhich leads to an aberrant heart
function, as evidenced by the bradycardia phenotype.(EH), Nkx2-5 (I–L), Nppa (M–P), Cx40 (Q–T) and cTnt (U–X) at E10.5 and at E11.5 in the
t atrium in the wild type (A, C) and is reduced or absent in the Shox2mutant (B, D). Tbx3
ever is absent in the Shox2 mutant (F, H) at both stages. Nppa, Cx40, and Nkx2-5 are
R, L, P, T), as compared to the wild type controls (I, M, Q, K, O, S). cTnt shows comparable
the arrows point to the SAN region, while the arrowheads point to the sinus valves. A,
Fig. 4. Shox2 overexpression downregulates Nkx2-5 expression. XNkx2-5 and XcTnI expressionwas analyzed by in situ hybridization in control embryos at stage 26 (A, E) and at stage
41 (C, G) and in GR-Shox2mRNA injected induced embryos at same stages (B, F, D, H). XNkx2-5 expression is clearly reduced at themidline of injected induced embryos at stage 26 (B),
as compared to control embryos (A). XcTnI expression is maintained in injected induced embryos laterally, but is absent at the midline at stage 26 (F), as compared to the controls (E).
At stage 41, XNkx2-5 expression is absent in injected induced embryos (D) compared to control embryos (C). XcTnI expression in injected induced embryos (D) is comparable to that
of control embryos (H). Altered gene expression is accompanied by the abnormal heart morphology when comparing control and injected induced embryos (C, D, G, H). Histological
transverse sections of Xenopus embryos showing loss of mesodermal cardiac progenitor cells in the ventral midline in injected induced embryos (B’, D’, arrowheads), as evidenced by
the loss of XNkx2-5 expression in the corresponding region when compared to control embryos (A’, C’, arrowheads). Scale bars represent 50 μm.
Table 1
Summary of the number of normal and abnormal embryos collected at stage 26 after





Total % Normal % Abnormal
Control 37 0 37 100 0
Gr-Shox2 38 0 38 100 0
Control DEX 64 2 66 97 3
Gr-Shox2 DEX 36 45 81 44 56
381R.A. Espinoza-Lewis et al. / Developmental Biology 327 (2009) 376–385Histological, cellular and molecular results indicate failure in the
differentiation process of pacemaker cells and lack of a deﬁned SAN.
Moreover, the ectopic Nkx2-5 expression and the down-regulated
Tbx3 expression, along with the ectopic expression of Nppa and Cx40,
suggest that the SAN in the mutant adopts an atrial working
myocardial fate.
Shox2 acts upstream of Nkx2-5 to regulate SAN differentiation
The early cardiac transcription factor Nkx2-5 is vital for the
differentiation of primary heart ﬁeld (PHF) cardiomyocytes (Komuro
and Izumo, 1993; Tanaka et al., 1999; Moses et al., 2001) and the
cardiac conduction system (Schott et al., 1998; Benson et al., 1999;
Watanabe et al., 2002). Recent studies suggest that the absence of
Nkx2-5 expression is necessary for the SAN formation (Mommersteeg
et al., 2007; Blaschke et al., 2007). The fact that the lack of Shox2
causes an ectopic expression of Nkx2-5 in the SAN (Blaschke et al.
2007; and this study) prompted us to test if Shox2 functions to
repress Nkx2-5. We took a gain-of-function approach by overexpres-
sing Shox2 driven by the rat cTnT promoter in developing mouse
embryos. This rat cTnT promoter has been shown to drive gene
expression speciﬁcally in the developing heart as early as E7.5 (Wang
et al., 1994, 2001; Jiao et al., 2003). Unexpectedly, of 65 total potential
transient transgenic embryos that were collected at E8.5 and E9.5,
only 6 were positive for the transgene but none of them exhibited
expression of the transgene in the heart (data not shown), suggesting
that the earlier transgenic expression of Shox2 might be lethal to the
embryos. To overcome this obstacle, we carried out the over-
expression experiment in Xenopus embryos using an inducible
system. Frog embryos were collected and injected with mRNA
synthesized from the GR-Shox2 construct. Nuclear translocation of
the fusion protein was induced by addition of Dexamethasone
(10 μM) into the embryo culture buffer. Induction was initiated at
stage 14, and embryos were harvested at stage 27 (early cardiac
formation) or stage 41 (late cardiac formation). At stage 27 injected
but un-induced embryos resembled control ones, while injectedinduced embryos show morphological abnormalities including a
reduced size of the head (data not shown). Whole mount in situ
hybridization for XNkx2-5 in control embryos showed the laterally
extended expression resembling wings connected at the ventral
midline by two small masses which will form the heart tube (Fig. 4A).
In contrast, XNkx2-5 expression in the injected induced embryos
maintained the lateral extension; however, the expression at the
midline was absent (Fig. 4B). Expression of cardiac troponin I (cTnI) in
control embryos shows an overlapping expression pattern with that
of XNkx2-5 at the midline indicating cardiac formation in this region
(Fig. 4E). In the injected induced embryos, expression of cTnI at the
midline was absent, but nevertheless it persisted in regions adjacent
to the midline (Fig. 4F). Histological sections of Xenopus embryos
clearly revealed that the loss of XNkx2-5 in the ventral midline
section correlates to the loss of a population of cells which
corresponds to mesodermal cardiac progenitors (Figs. 4A’–D’). This
observation is consistent with previous results obtained with over-
expression of XNkx2-5 dominant negative repressor derivatives in
Xenopus embryos (Fu et al., 1998) and morpholino knockdown against
nkx2.5 in zebraﬁsh (Targoff et al., 2008). A summary of the number of
normal and abnormal embryos collected at stage 26 after injection
and in situ hybridization is shown in Table 1. Later in development, at
stage 41, injected induced embryos exhibited a smaller tubular or
slightly chambered heart as compared to control samples and very
slow and irregular heart beat was observed at the moment of
Fig. 5. Shox2 represses the activity of the Nkx2-5 promoter in cell cultures. (A) Neonatal rat cardiomyocytes and H9c2 cells were utilized. Co-transfection of with 100 ng of pGL3 basic
vector as controls or Nkx2-5-Luc construct, with Myc-Shox2 expression vector at 50 ng, and 200 ng was performed. Reporter gene expression shows a progressive signiﬁcant
reduction in the activity of the Nkx2-5 promoter on both cell culture systems (⁎=Pb0.001 at 200 ng). The Yaxis represents activity of the Nkx2-5 promoter relative to the background
after normalization. B) Reporter gene expression assay shows that the activity of the truncated Nkx2-5 promoters when co-transfected with myc-Shox2 (0, 200 and 400 ng/μl) follows
a similar trend to the 3.3-kb promoter (⁎, signiﬁcant difference, Pb0.05).
Fig. 6. Shox2 regulates the SAN genetic program through repression of Nkx2-5. A genetic
hierarchy model places Shox2 downstream of Pitx2 but upstream of Nkx2-5 in the
regulation of SAN formation. Black arrows represent the up- or downregulation of
expression depending on the expression or lack thereof of the upstream gene.
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while cTnI expression was unaltered (Figs. 4C, D, G, H). These results
resemble and are consistent with the phenotype of Nkx2-5 null mice
that also present cardiac arrest after cardiac looping and poor cardiac
development (Tanaka et al., 1999).
Shox2 acts as a transcriptional repressor on the Nkx2-5 promoter
To determine if Shox2 has a direct or indirect effect on the
expression of Nkx2-5, Luciferase reporter gene expression assays
were carried out. A reporter construct harboring a 3.3-kb mouse
Nkx2-5 upstream fragment linked to the luciferase reporter gene
(Nkx2-5-Luc) was co-transfected with different concentrations of
myc-Shox2 into neonatal rat cardiomyocytes or into H9c2 rat
cardiogenic cells. H9c2 cells were induced to differentiate 24 h after
transfection by exposure to DMEM culture medium supplemented
with 1% horse serum. The induction of differentiation is necessary to
induce the expression of the Nkx2-5 promoter (Lim et al., 2008). The
reporter gene expression assays clearly demonstrated a concentra-
tion-dependent repression of the Nkx2-5 promoter activity by Shox2
in both types of cells (Fig. 5A). While the expression of reporter gene
in H9c2 cells was markedly lower than that in rat cardiomyocytes, the
results are consistent in both cell lines. Base on the criteria for
homeobox genes binding sites, Shox2 might bind to a consensus “P”
site, deﬁned as a palindromic “ATTA(N)nTAAT” sequence in which “N”
is any nucleotide and “n” is the number of nucleotides which
separate the ATTA palindromic sequence (Rao et al., 2001), or to a
consensus “TAATTA” site (Berger et al., 2008). Four putative Shox2
binding sites within the Nkx2-5 promoter were identiﬁed and
labeled BS-I–IV. To determine if any of these sites mediates the
repressive effect of Shox2 on the Nkx2-5 promoter, we eliminated
these potential binding sites by site-directed mutagenesis, and by
promoter deletion to engineer two shorter promoters, a 2.9 kb
promoter which does not contain putative binding sites I–III and a
2.1 kb promoter which does not contain any putative binding site.
Co-transfection of mutated or truncated promoters with different
concentrations of Shox2 demonstrate that either mutant or
truncated promoters responded in the same fashion as the 3.3-kb
original promoter (Fig. 5B and data not shown). Promoter activities
were down-regulated in a Shox2 concentration-dependent manner.
Taken together, our results suggest that Shox2 indeed represses the
Nkx2-5 promoter activity. However, Shox2 might not directly interact
with the Nkx2-5 promoter.Discussion
Histological analyses of the Shox2−/− heart revealed early cardiac
structural malformation including hypoplastic SAN and sinus valves,
defective atrial myocardial wall and at later developmental stages a
signiﬁcantly enlarged right atrium. These results are in concordance
with results obtained by Blaschke et al. (2007). Since Shox2
expression in the heart is restricted to the sinus venosus, the SAN
and the sinus valves, it indicates that the structural defects observed
in other regions are most likely a secondary effect caused by the
absence of a functional pacemaker and hypoplastic sinus valves.
Malformation of the SAN and sinus valves is attributed to a
signiﬁcantly decreased level of cell proliferation, consistent with a
role previously reported for Shox2 in the developing palate, limbs and
the TMJ (Yu et al., 2005, 2007; Gu et al., 2008). The sinus valves are
composed of two myocardial layers that have different physical
characteristics (Gallego et al., 1997) with one being continuous with
the atrial working myocardium and the other continuous with the
venous dorsal wall of the atrium containing the pacemaker area.
Reduced growth observed in both of the sinus valves layers and the
SAN region of the Shox2−/− heart suggests that growth of the
myocardial layer uses the venous layer as a template to elongate
and “mature” before the recession and integration of the entire valve
in the dorsal wall of the right atrium.
Reduction and possibly absence of a functional SAN leads to a
reduced heart beat rate and embryonic lethality in the Shox2 mutant
embryo. This phenotype resembles symptomatic sinus bradycardia
related to sick sinus syndrome in humans which affects the capability
of the heart to contract at a normal rate or below 55 beats per minute
(Savalieva and Camm, 2008).Hcn1-4molecules are responsible for the
generation of the “funny” current which is characteristic of the
pacemaker activity (Accili et al., 2002). Hcn4 expression in the SAN is
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characteristics when overexpressed in cell cultures (Santoro and
Tibbs, 1999; Santoro et al., 2000; Moosmang et al., 2001; Stieber et al.,
2003; Liu et al., 2007). A mutation in the cAMP binding site of the
human HCN4 gene was identiﬁed as the cause of sinus bradycardia
and sick sinus syndrome in a familial case (Milanesi et al., 2006).
Moreover, mice deﬁcient in Hcn4 die between E9.5 and E11.5
presenting a similar electrophysiological phenotype with lower
heart beat rate and slower pacemaker kinetics as compared to the
wild type controls (Stieber et al., 2003). In this study we demonstrate
that the expression of Hcn4 is down-regulated in the Shox2−/− heart
beginning at E10.5. Taking this into consideration along with the fact
that Hcn4 is required for the regulation of the normal intrinsic electric
ﬁring of the SAN, we conclude that the loss of Hcn4 is the cause for the
slow ﬁring of the SAN cells and the consequent slowing of the heart
beat rate in Shox2−/−. This phenomenon is accompanied by the altered
expression of several genes that have been used to demarcate the
location of the SAN and pacemaker. Tbx3 is expressed in the cardiac
conduction system including the SAN (Hoogaars et al., 2004). In
contrast, the expression of Nkx2-5, Nppa and Cx40 is widely seen in
the myocardium but not in the SAN region (Soufan et al., 2004; Liu et
al., 2007). The absence of Hcn4 and Tbx3 expression and the ectopic
expression of Nkx2-5, Nppa and Cx40 in the sinus node of the Shox2−/−
heart indicate the lack of a deﬁnable SAN region. It has been reported
that Tbx3 imposes a sinoatrial fate to myocardial cells (Hoogaars et al.
2007), however it was concluded that its function is to shield the SAN
from becoming atrial working myocardium and preserve an embryo-
nic phenotype. Additionally in Tbx3−/− hearts the formation of a
primordial SAN is observed and expression of Hcn4 is maintained
beyond the embryonic stage in which Shox2mutation becomes lethal.
These observations suggest that Shox2 might act earlier than Tbx3 in
the formation of the SAN and the pacemaker. Alterations in gene
expression pattern observed in the Shox2−/− heart are not likely
attributed to a speciﬁc loss of potential SAN progenitor cells, since the
mutant heart does not exhibit an increased level of apoptosis.
However, it could be argued that a low level of cell proliferation
might account for the lack of a deﬁnable SAN and the lack of
expression of certain genes. Nevertheless, positive expression of Hcn4
in the Shox2−/− heart at E10.5 reveal that progenitor cells are indeed
present and the genetic pattern of other genes is similar at E10.5 and
at E11.5 when Hcn4 is absent. Our histological, functional and
molecular results combined with observations detailed above indicate
that cells within the SAN region of the Shox2−/− heart fail to
differentiate into specialized pacemaker cardiomyocytes but rather
adopt the fate of the atrial working myocardium which places Shox2
as a key and upstream intrinsic factor in a very speciﬁc and important
niche in the molecular network that regulates the differentiation of
SAN cells. It was proposed that Pitx2, which is expressed in the left
side of the heart (Ryan et al., 1998; Yu et al., 2001), acts to determine
the asymmetrical positioning of the sinus node to the right side,
thereby preventing the left atrium to assume right side characteristics
(Mommersteeg et al., 2007). Thus, expression of Pitx2 in the left side
of the heart restricts Shox2 expression to the sinus node in the right
atrium. This conclusion is supported by the observation that in Pitx2
mutants, an ectopic Shox2 expression domain is seen in the left
atrium, mirror-imaging the original one in the sinus node in the right
atrium and that Pitx2 expression in the Shox2−/− heart is unaltered
(Espinoza-Lewis and Chen, unpublished observations). Together with
previous studies that place Tbx3 and Hcn4 downstream of Nkx2-5
(Mommersteeg et al., 2007), we present a model integrating Pitx2,
Shox2, Nkx2-5, Tbx3, andHcn4 that operates to regulate the pacemaker
development (Fig. 6). In this model, the expression of Pitx2 leads to
the inhibition of the right side program in the left side, thus the
absence of Pitx2 in the right side leads to the activation of Shox2
expression, which in turn acts to repress Nkx2-5. The repression of
Nkx2-5 further allows for the activation of the differentiation programin the sinus node where Tbx3 further inhibits the expression of Nppa
and Cx40.
Early histological studies (van Mierop and Gessner, 1970; Challice
and Virágh, 1973) and recent molecular analyses indicate that SAN
cells are recruited into the venous pole of the heart, and that this
population is Nkx2-5 negative and Tbx18 positive (Christoffels et al.,
2006). Thus, the question pertaining to how these cells become Nkx2-
5 negative arises. Here, gain-of-function studies in Xenopus embryos
as well as in cell cultures reveal that Shox2 is able to repress the
expression of Nkx2-5. In Xenopus embryos overexpression of Shox2
causes the down-regulation of XNkx2-5 in the ventral middle section,
however the lateral expression remains. Later in development the
resulting heart is small and tubular. These observations are consistent
with several previous studies inwhich, 1) overexpression of dominant
negative derivatives of XNkx2-5 results in the loss of mesodermal
cardiac progenitor cells; 2) anti-nkx2.5 morpholino injection in
zebraﬁsh results in elongation abnormalities of the tubular heart,
disorganized atrial cells and an enlarged ventricle; and 3) Nkx2-5 null
mutation in mice leads to cardiac arrest after cardiac looping and the
formation of an abnormal, small and tubular heart. Additionally,
Luciferase reporter assays show that indeed Shox2 represses the
activity of the Nkx2-5 promoter. Mutations at the putative Shox2
binding sites and truncations of the promoter to eliminate these
binding sites have no effect in the repressive activity of Shox2 on the
Nkx2-5 promoter. It is known that homeobox genes have transcrip-
tional activity either by binding directly to the DNA or by binding to
other proteins and acting as co-factors (del Bene and Wittbrodt,
2005). The Runx2 homeobox gene has been shown to regulate gene
expression by direct binding to the Osteocalcin promoter (Ducy et al.,
1997) or by acting as a co-factor to SRF (Serum Response Factor, a
MADS box transcription factor) to prevent the Myocardin-induced
myogenic genetic program and to promote the activation of the
osteogenic genetic program (Tanaka et al., 2008). It is also likely that
Shox2 interacts with other factors in order to repress the expression
of Nkx2-5. This repressive activity of Shox2 on Nkx2-5 facilitates the
expression of a genetic program to maintain the SAN fate and shield
the SAN from becoming working atrial myocardium.
Our results demonstrate that Shox2 is essential for the proper
formation and differentiation of the SAN, in addition to regulate a
genetic network through the indirect repression of Nkx2-5 tomaintain
a SAN muscle fate. Additionally, this study provides one more insight
for future genetic therapeutic approach against deﬁciencies in the SAN
function in humans.
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